Is radical prostatectomy a viable therapeutic option in clinically locally advanced (cT3) prostate cancer?

BJU International

Volumn 106, Issue 11, 2010, Pages 1596-1600

  Xylinas, Evanguelos ^a   Daché, Arnaud ^a   Rouprêt, Morgan ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

prostate cancer; prostate specific antigen; radical prostatectomy; recurrence; T3

Indexed keywords

ANTIANDROGEN; DOCETAXEL; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER PATIENT; CANCER STAGING; DIGITAL RECTAL EXAMINATION; ERECTILE DYSFUNCTION; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HUMAN; MEDICAL SOCIETY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHYSICAL EXAMINATION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT OUTCOME;

HUMANS; MALE; NEOPLASM STAGING; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME;

EID: 78649260560     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09630.x     Document Type: Review

References (35)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106 - 30
2. Hankey BF, Feuer EJ, Clegg LX, et al. Cancer surveillance series: interpreting trends in prostate cancer - part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999; 91: 1017 - 24
3. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103 - 6
4. Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H,. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 2005; 95: 751 - 6
5. Loeb S, Smith ND, Roehl KA, Catalona WJ,. Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer. Urology 2007; 69: 1170 - 5
6. Carver BS, Bianco FJ Jr, Scardino PT, Eastham JA,. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J Urol 2006; 176: 564 - 8
7. Freedland SJ, Partin AW, Humphreys EB, Mangold LA, Walsh PC,. Radical prostatectomy for clinical stage T3a disease. Cancer 2007; 109: 1273 - 8
8. Hsu CY, Joniau S, Oyen R, Roskams T, Van Poppel H,. Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. Eur Urol 2007; 51: 121 - 8
9. Xylinas E, Drouin S, Comperat E, et al. Oncologic control after radical prostatectomy in men with clinical T3 prostate cancer: a single-center experience. BJU Int 2009; 103: 1173 - 8
10. Hsu CY, Joniau S, Oyen R, Roskams T, Van Poppel H,. Detection of clinical unilateral T3a prostate cancer - by digital rectal examination or transrectal ultrasonography? BJU Int 2006; 98: 982 - 5
11. Bloch BN, Furman-Haran E, Helbich TH, et al. Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging - initial results. Radiology 2007; 245: 176 - 85
12. Sala E, Eberhardt SC, Akin O, et al. Endorectal MR imaging before salvage prostatectomy: tumor localization and staging. Radiology 2006; 238: 176 - 83
13. Heijmink SW, Futterer JJ, Hambrock T, et al. Prostate cancer: body-array versus endorectal coil MR imaging at 3 T - comparison of image quality, localization, and staging performance. Radiology 2007; 244: 184 - 95
14. Cornud F, Flam T, Chauveinc L, et al. Extraprostatic spread of clinically localized prostate cancer: factors predictive of pT3 tumor and of positive endorectal MR imaging examination results. Radiology 2002; 224: 203 - 10
15. Descazeaud A, Peyromaure M, Vieillefond A, Bernard D, Zerbib M,. Does transrectal MRI before radical prostatectomy modify the operative technique to decrease the positive surgical margin rate. Prog Urol 2006; 16: 564 - 7
16. Oyen RH, Van Poppel HP, Ameye FE, Van de Voorde WA, Baert AL, Baert LV,. Lymph node staging of localized prostatic carcinoma with CT and CT-guided fine-needle aspiration biopsy: prospective study of 285 patients. Radiology 1994; 190: 315 - 22
17. Bolla M, Van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005; 366: 572 - 8
18. Heidenreich A, Varga Z, Von Knobloch R,. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 2002; 167: 1681 - 6
19. Stone NN, Stock RG, Unger P,. Laparoscopic pelvic lymph node dissection for prostate cancer: comparison of the extended and modified techniques. J Urol 1997; 158: 1891 - 4
20. Corvin S, Schilling D, Eichhorn K, et al. Laparoscopic sentinel lymph node dissection-a novel technique for the staging of prostate cancer. Eur Urol 2006; 49: 280 - 5
21. Dreicer R, Magi-Galluzzi C, Zhou M, et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 2004; 63: 1138 - 42
22. Chi KN, Chin JL, Winquist E, Klotz L, Saad F, Gleave ME,. Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol 2008; 180: 565 - 70
23. Klotz LH, Goldenberg SL, Jewett MA, et al. Long-term follow-up of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 2003; 170: 791 - 4
24. Schulman CC, Debruyne FM, Forster G, Selvaggi FP, Zlotta AR, Witjes WP,. 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol 2000; 38: 706 - 13
25. Van Poppel H,. Neoadjuvant hormone therapy and radical prostatectomy: the jury is still out. Eur Urol Suppl 2001; 39: 10 - 4
26. Shelley MD, Kumar S, Wilt T, Staffurth J, Coles B, Mason MD,. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev 2009; 35: 9 - 17
27. Messing EM, Manola J, Yao J, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006; 7: 472 - 9
28. Morgan SC, Waldron TS, Eapen L, Mayhew LA, Winquist E, Lukka H,. Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: a systematic review and meta-analysis. Radiother Oncol 2008; 88: 1 - 9
29. Bolla M, Van Poppel H, Collette L, et al. European Organization for Research and Treatment of Cancer. Postoperative radiotherapy after radical prostatectomy: a randomized controlled trial (EORTC trial 22911). Lancet 2005; 366: 572 - 8
30. Wiegel T, Bottke D, Willich N, et al. Phase III results of adjuvant radiotherapy (RT) versus "wait and see" (WS) in patients with pT3 prostate cancer following radical prostatectomy (RP) (ARO96-02/AUO AP09/95)). J Clin Oncol 2005; 23: 16s (suppl; abstr 5060)
31. Aus G, Abbou CC, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol 2005; 48: 546 - 51
32. Swanson GP, Thompson IM, Tangen C, et al. Update of SWOG 8794: adjuvant radiotherapy for pT3 prostate cancer improves metastasis free survival. Int J Radiat Oncol Biol Phys 2008; 72: S31
33. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term follow-up of a randomized clinical trial. J Urol 2009; 181: 956 - 62
34. Penson DF, McLerran D, Feng Z, et al. 5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study. J Urol 2008; 179 (5 Suppl.): S40 - 4
35. Audenet F, Comperat E, Seringe E, et al. Oncologic control obtained after radical prostatectomy in men with a pathological Gleason score >/= 8: a single-center experience. Urol Oncol 2009; [Epub ahead of print] doi:10.1016/j.urolonc.2009.09.011